♦ Pharmaceutical Industry Research

Unbiased assessments of the challenges and potential for pharmacovigilance
Detailed discussions of where pharmacovigilance is heading from 2009 onwards
Analyses and discussion of the relevant challenges facing the pharmaceutical industry
Analyses and discussion of how pharmacovigilance can influence the development, marketing and use of pharmaceuticals
Discussion of personalized medicine, and how pharmacovigilance can be utilized in better-targeted medicine
Discussion of how pharmacovigilance can contribute to live licensing
Views of experts in the field, with full texts of interviews from the visiongain survey
Forecasts of how pharmacovigilance costs will change over the next 15 years
Insight into public relations challenges faced by the industry, and how pharmacovigilance can help address those matters
Analyses of how actual risk and public perception interact

Discussion of the current Japanese pharmaceutical market in the context of the global pharma market
Forecast of the overall Japanese pharmaceutical market from 2008 to 2023
Drivers and restraints facing the Japanese market
Opportunities and threats facing the Japanese market
Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023
Individual forecasts of the leading drug classes from 2008 to 2023
The potential of generics manufacturers to penetrate this market
Relevant pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs

Analyses of the existing market value for stem cells
Analyses of the potential market value of stem cell therapies, including detailed revenue forecasts from 2009 to 2024
Forecasts for existing stem cell markets, including private cord blood banks and Osiris Therapeutics and NuVasive's Osteocel
Discussions of ethical complications and situations that influence the way stem cell medicine is perceived, researched and conducted
Analyses of key organizations, suppliers and relevant national laws
Expert opinions from original research interviews with key opinion leaders in stem cells research and technology
Informed analyses of the strengths and weaknesses of the technologies from 2009 onwards
Balanced assessments of commercial drivers and restraints in the stem cells field.

More info on the stem cell market

Antiviral drugs assessment and opportunities
Key industrial players in the global antivirals market
Forecasts of global antivirals market from 2008-2023, including in-house developed forecasts of the leading therapeutic agents
Forecasts for the antiviral therapies in the seven leading developed pharmaceutical country markets and two leading developing markets
Drivers and opportunities in the global antivirals market
Restraints and threats in the global antivirals market
Key opinion from relevant experts - full interview transcripts are included with the report (unavailable anywhere else)
Coverage of pipeline developments in the antivirals market, with discussion of trends from the present onwards

The value of the contract pharma business market and its principal market segments from 2008 to 2023, with detailed forecasts and growth analyses
Market drivers and restraints, including a comprehensive SWOT analysis
Comprehensive views of key opinion leaders on contract pharma, including leading companies, with full interview transcripts from our in-depth survey worldwide
The companies involved in contract pharma business and their business strategy
The present state of contract pharma business and future trends there
What contract pharma opportunities exist for market entrants, both established companies and newcomers
The main concerns for outsourcing clinical trials to CROs
Changes in contract pharma regulations

Sales forecasts for vaccines by disease area, brand and country, including novel therapeutic vaccines
Examination of strengths, weakness, opportunities and threats facing the vaccine industry
Expert opinion from key-opinion leaders in the field
In-depth analysis of the vaccine pipeline
Analysis of the prospects for therapeutic vaccines
Geographical breakdown of the vaccine market, including the leading emerging markets of China and India
Coverage of future trends in vaccine technology, formulation and manufacturing
Identification of key industrial players in the vaccines market.

More info on the vaccines market

New drug pricing and price revision processes explained
Written by an acknowledged expert on the Japanese market with 20 years’ experience
Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008
Incorporates all pricing rule changes that came into effect from April 2008
Pro-generic measures critically appraised
Key role of wholesalers and how they are paid clarified
Prospects for future reform to the P&R processes discussed

Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for
Separate sections on England, Scotland, Wales and Northern Ireland
Full coverage of the NHS plus two of the largest private providers
Explanation of tendering, contracting, contract adjudication and other aspects of procurement for both brands and generics
Clarification of the complex English funding system, Payment by Results
Special focus on oncology
What discounts hospitals expect and why value-added tax is a concern
Features on risk-sharing schemes and on the boom in homecare services

The UK’s complex decision-making processes for funding of medicines
The procedures and outcomes of the three HTA bodies, NICE, SMC and AWMSG
How and why the 2009 PPRS evolved in the way it did, and what this means for companies selling medicines to the NHS
The pros and cons of joining the voluntary or alternative statutory scheme
All the changes in the new PPRS and the prospects for the more novel but contentious parts, including flexible pricing, patient access schemes and generic substitution
What jargon including ‘end-of-life treatment’, ‘horizon scanning’, ‘NICE blight’,‘OFT wedge’ ‘outturn’, ‘QALY’, ‘safety value’ and ‘top-up’ actually mean
Other cost containment measures impacting on prescribers, patients and the distribution chain